|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9792
|
|
pubmed:dateCreated |
2011-8-22
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Decreased systolic function is central to the pathogenesis of heart failure in millions of patients worldwide, but mechanism-related adverse effects restrict existing inotropic treatments. This study tested the hypothesis that omecamtiv mecarbil, a selective cardiac myosin activator, will augment cardiac function in human beings.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1474-547X
|
|
pubmed:author |
pubmed-author:BeeRachelR,
pubmed-author:ChenMichael MMM,
pubmed-author:ClarkeCyril PCP,
pubmed-author:ElliottLyndseyL,
pubmed-author:EscandonRafael DRD,
pubmed-author:GoldmanJonathan HJH,
pubmed-author:HabibzadehMohammad RezaMR,
pubmed-author:LeeJacqueline HJH,
pubmed-author:MalikFady IFI,
pubmed-author:SaikaliKhalil GKG,
pubmed-author:SchillerNelson BNB,
pubmed-author:TeerlinkJohn RJR,
pubmed-author:WolffAndrew AAA
|
|
pubmed:copyrightInfo |
Copyright © 2011 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
378
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
667-75
|
|
pubmed:meshHeading |
pubmed-meshheading:21856480-Adult,
pubmed-meshheading:21856480-Cardiac Myosins,
pubmed-meshheading:21856480-Cross-Over Studies,
pubmed-meshheading:21856480-Dose-Response Relationship, Drug,
pubmed-meshheading:21856480-Double-Blind Method,
pubmed-meshheading:21856480-Humans,
pubmed-meshheading:21856480-Infusions, Intravenous,
pubmed-meshheading:21856480-Male,
pubmed-meshheading:21856480-Maximum Tolerated Dose,
pubmed-meshheading:21856480-Middle Aged,
pubmed-meshheading:21856480-Myocardial Contraction,
pubmed-meshheading:21856480-Stroke Volume,
pubmed-meshheading:21856480-Systole,
pubmed-meshheading:21856480-Urea,
pubmed-meshheading:21856480-Ventricular Function, Left,
pubmed-meshheading:21856480-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.
|
|
pubmed:affiliation |
Section of Cardiology, San Francisco Veterans Affairs Medical Center, University of California, San Francisco, CA 94121-1545, USA. john.teerlink@ucsf.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
